Internship
Technology Excellence & Innovation Management Intern
Updated on 9/3/2026
Zeiss
1,001-5,000 employees
Manufactures high-precision optical instruments and devices
No salary listed
Oberkochen, Germany
In Person
Bachelor's
 Project & Program Management (1) |
|---|
Get referred to Zeiss
See people who can refer or advise you
- Currently pursuing a degree in business administration, innovation management, communications, business informatics, project management, or a comparable program.
- Strong interest in innovation, new technologies, project management, communication, and knowledge management.
- Strong organizational and analytical abilities and a structured working style.
- Strong communication skills and enjoyment of cross-functional collaboration.
- Very good German and English language skills.
- Solid knowledge of Microsoft Office, especially PowerPoint and Excel, as well as Miro, Teams, or SharePoint.
- Basic understanding of technical concepts, including templates, interfaces, and data protection.
- Ability to use artificial intelligence tools appropriately for research, text formulation such as user stories, data analysis, or process automation.
- Support communication and visibility for initiatives of the highest-level R&D and innovation career track.
- Maintain and further develop knowledge-management systems.
- Promote transparency, documentation, and knowledge exchange across teams and business units.
- Support and co-organize workshops, community formats, and strategic events.
- Track project plans, milestones, timelines, and measures.
- Create presentations, reports, and communication materials.
- Help shape structured working methods, governance processes, and continuous improvements.
- Experience with content management systems such as TYPO3, Contentful, Sitecore, Adobe AEM, or WordPress.
- Experience using artificial intelligence applications or tools.
ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$67.7M
Headquarters
Oberkochen, Germany
Founded
2001
Get referred to Zeiss
See people who can refer or advise you
Simplify's Take
What believers are saying
- ZEISS reported 5.841 billion euros revenue in H1 2025/26, up 1% year over year.
- China approved ARTEVO 750 and 850 in February 2026, expanding ophthalmic sales access.
- ZEISS launched CLINIC 360 and Collaborative Care in 2026, increasing subscription software revenue.
What critics are saying
- Carl Zeiss Meditec plans 600-1,000 job cuts through 2028/29 after weaker China and U.S. demand.
- Monument Peak sued Carl Zeiss AG on February 6, 2026 over Kodak-related imaging patents.
- Dependence on ASML leaves ZEISS SMT exposed if High-NA ramps slip past 2026.
What makes Zeiss unique
- ZEISS SMT remains ASML’s exclusive optics supplier for High-NA EUV in 2026.
- ZEISS Medical Technology owns integrated ophthalmology workflows across ARTEVO, IOLMaster, FORUM, and CLINIC 360.
- ZEISS combines precision optics, surgical hardware, and cloud software across medicine and semiconductors.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 4%ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.
ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.
ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.
ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.
ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.